Mechanistic Cardiac Magnetic Resonance Study to Investigate the Effects of Empagliflozin in Patients with Heart Failure

Chief investigator:Stefan Neubauer

Co-investigators:Rury Holman
Masliza Mahmod

Sponsor:Boehringer Ingelheim

Funder:Boehringer Ingelheim

Reference number:NCT03332212

Heart failure is a global epidemic affecting an estimated 26 million people worldwide and one of the leading causes of hospitalisation in Western countries. The EMPA-REG OUTCOME study showed that a drug called empagliflozin, currently used to treat type 2 diabetes, might help people who suffer from heart failure

The EMPA-VISION study aims to investigate changes in heart function in patients with chronic heart failure when they take Empagliflozin. The results of this study combined with other ongoing studies, could make Empagliflozin a promising new treatment for patients with heart failure.


This phase III randomised, double-blind placebo-controlled trial will compare the effect of 12 weeks once daily administration of Empagliflozin to placebo on heart function. Participants will be assessed before and after treatment using cutting-edge Magnetic resonance imaging (MRI) technology.

Launched on 1st March 2018, we expect results from this trial will be available in 2020.


To investigate the mechanism by which Empagliflozin improves heart failure related outcomes.

Currently recruiting

Contact:Dr Masliza Mahmod
Dr Moritz Hundertmark

Telephone:01865 223836



60 patients with chronic heart failure (without severe coronary artery disease) aged 18 years or older to attend 5-7 visits at the John Radcliffe hospital over 15 weeks.

The trial is co-ordinated by DTU in collaboration with the Oxford Centre for Clinical Magnetic Resonance Research (OCMR).


EMPA-VISION webpage live as part of DTU website redesign


The newly updated DTU website now includes a webpage for each of our trials.

For ongoing trials, you can find out what type of participants we are looking for and contact details if you are interested in taking part....

[Read more...]

EMPA-VISION Trial Launched


Launched on 1st March 2018, we expect results from this trial will be available in 2020.

[News archive]